Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 4, 2006, Pages 1346-1355

  Howard, Nigel ^b   Abell, Chris ^b   Blakemore, Wendy ^a   Chessari, Gianni ^a   Congreve, Miles ^a   Howard, Steven ^a   Jhoti, Harren ^a   Murray, Christopher W ^a   Seavers, Lisa C A ^a   Van Montfort, Rob L M ^a  

^a ASTEX PHARMACEUTICALS   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; LIGAND; MELAGATRAN; N [3 (5 CHLORO 2 TETRAZOL 1 YLBENZYLAMINO) 2 HYDROXY 4 PHENYLBUTYL] 4 METHOXY 2,3,6 TRIMETHYLBENZENESULFONAMIDE; N [3 (5 CHLORO 2 TETRAZOL 1 YLBENZYLAMINO) 2 HYDROXY 4 PHENYLBUTYL] 4 METHOXYBENZENESULFONAMIDE; SERINE PROTEINASE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; XIMELAGATRAN;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; HIGH THROUGHPUT SCREENING; IC 50; LIGAND BINDING; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CARBAMATES; CRYSTALLOGRAPHY, X-RAY; DATABASES, FACTUAL; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TETRAZOLES; THROMBIN;

EID: 33144470698     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050850v     Document Type: Article

References (56)

1. Bode, W. The structure of thrombin, a chameleon-like proteinase. J. Thromb. Haemostasis [Online] 2005, Epub ahead of print, 09/05/2005.
2. Stubbs, M. T.; Bode, W. The clot thickens: clues provided by thrombin structure. Trends Biochem. Sci. 1995, 20, 23-28.
3. Riester, D.; Wirsching, F.; Salinas, G.; Keller, M.; Gebinoga, M.; Kamphausen, S.; Merkwirth, C.; Goetz, R.; Wiesenfeldt, M.; Sturzebecher, J.; Bode, W.; Friedrich, R.; Thurk, M.; Schwienhorst, A. Thrombin inhibitors identified by computer-assisted multiparameter design. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 8597-8602.
4. Steinmetzer, T.; Sturzebecher, J. Progress in the development of synthetic thrombin inhibitors as new orally active anticoagulants. Curr. Med. Chem. 2004, 11, 2297-2321.
5. Stassen, J. M.; Arnout, J.; Deckmyn, H. The hemostatic system. Curr. Med. Chem. 2004, 11, 2245-2260.
6. Matsuo, T.; Koide, M.; Kario, K. Development of argatroban, a direct thrombin inhibitor, and its clinical application. Semin. Thromb. Hemostasis 1997, 23, 517-522.
7. Sorbera, L. A.; Bayes, M. C. J.; Silvestre, J. Melagatran and Ximelagatran. Drugs Future 2001, 26, 1155-1170.
8. Dullweber, F.; Stubbs, M. T.; Musil, D.; Sturzebecher, J.; Klebe, G. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J. Mol. Biol. 2001, 313, 593-614.
9. Sturzebecher, J.; Hauptmann, J.; Steinmetzer, T. Thrombin. In Proteinase and Peptidase Inhibition; Smith, H. J., Simons, C., Eds.; Taylor and Francis: London, 2002: pp 178-201.
10. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315.
11. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The design of leadlike combinatorial libraries. Angew. Chem.. Int. Ed. 1999, 38, 3743-3748.
12. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 2001, 41, 856-864.
13. Hajduk, P. J.; Sheppard, G.; Nettesheim, D. G.; Olejniczak, E. T.; Shuker, S. B.; Meadows, R. P.; Steinman, D. H.; Carrera, G. M., Jr.; Marcotte, P. A.; Severin, J.; Walter, K.; Smith, H.; Gubbins, E.; Simmer, R.; Holzman, T. F.; Morgan, D. W.; Davidsen, S. K.; Summers, J. B.; Fesik, S. W. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 1997, 119, 5818-5827.
14. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins; SAR by NMR. Science 1996, 274, 1531-1534.
15. Carr, R.; Jhoti, H. Structure-based screening of low-affinity compounds. Drug Discovery Today 2002, 7, 522-527.
16. Lesuisse, D.; Lange, G.; Deprez, P.; Benard, D.; School, B.; Delettre, G.; Marquette, J. P.; Broto, P.; Jean-Baptiste, V.; Bichet, P.; Sarubbi, E.; Mandine, E. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 2002, 45, 2379-2387.
17. Blundell, T. L.; Abell, C.; Cleasby, A.; Hartshorn, M. J.; Tickle, I. J.; Parasini, E.; Jhoti, H. High-throughput X-ray crystallography for drug discovery. In Drug Design: Special Publication; Flower, D. R., Ed.; Royal Society of Chemistry: Cambridge, U.K., 2002; pp 53-59.
18. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery. Nat. Rev. Drug Discovery 2004, 3, 660-672.
19. Erlanson, D. A.; McDowell, R. S.; O'Brien, T. Fragment-based drug discovery. J. Med. Chem. 2004, 47, 3463-3482.
20. Zartler, E. R.; Shapiro, M. R. Fragnomics: fragment-based drug discovery. Curr. Opin. Chem. Biol. 2005, 9, 366-370.
21. Nienaber, V. L.; Richardson, P. L.; Klighofer, V.; Bouska, J. J.; Giranda, V. L.; Greer, J. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nat. Biotechnol. 2000, 18, 1105-1108.
22. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A "rule of three" for fragment-based lead discovery? Drug Discovery Todav 2003, 8, 876-877.
23. Muchmore, S. W.; Olson, J.; Jones, R.; Pan, J.; Blum, M.; Greer, J.; Merrick, S. M.; Magdalinos, P.; Nienaber, V. L. Automated crystal mounting and data collection for protein crystallography. Struct. Folding Des. 2000. 8, R243-R246.
24. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography. J. Med. Chem. 2005, 48, 403-413.
25. Gill, A. L.; Frederickson, M.; Cleasby, A.; Woodhead, S. J.; Carr, M. G.; Woodhead, A. J.; Walker, M. T.; Congreve, M. S.; Devine, L. A.; Tisi, D.; O'Reilly, M.; Seavers, L. C. A.; Davis, D. J.; Curry, J.; Anthony, R.; Padova, A.; Murray, C. W.; Carr, R. A. E.; Jhoti, H. Identification of Novel p38α MAP Kinase Inhibitors using fragment-based lead generation. J. Med. Chem. 2004, 48, 414-426.
26. Szczepankiewicz, B. G.; Liu, G.; Hajduk, P. J.; Abad-Zapatero, C.; Pei, Z.; Xin, Z.; Lubben, T. H.; Trevillyan, J. M.; Stashko, M. A.; Ballaron, S. J.; et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 2003, 125, 4087-4096.
27. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: current status and future prospects. J. Med. Chem. 2000, 43, 305-341.
28. Hartshorn, M. J. AstexViewer: a visualisation aid for structure-based drug design. J. Comput.-Aided Mol. Des. 2002. 16, 871-881.
29. Watson, P.; Verdonk, M. L.; Hartshorn, M. J. A web-based platform for virtual screening. J. Mol. Graphics Modell. 2003, 22, 71-82.
30. Verdonk, M. L.; Cole, J. C.; Hartshorn, M.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003. 52, 609-623.
31. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
32. Baxter, C. A.; Murray, C. W.; Clark, D. E.; Westhead, D. R.; Eldridge, M. D. Flexible docking using Tabu search and an empirical estimate of binding affinity. Proteins 1998, 33, 367-382.
33. Sanderson, P. E.; Cutrona, K. J.; Dyer, D. L.; Krueger, J. A.; Kuo, L. C.; Lewis, S. D.; Lucas, B. J.; Yan, Y. Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the "distal binding pocket". Bioorg. Med. Chem. Lett. 2003, 13, 161-164.
34. Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.; Krueger. J. A.; Cooper, C. M.; Vacca, J. P. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the Pl position. J. Med. Chem. 1998. 41, 3210-3219.
35. Young, M. B.; Barrow, J. C.; Glass, K. L.; Lundell, G. F.; Newton, C. L.; Pellicore, J. M.; Rittle, K. E.; Selnick, H. G.; Stauffer, K. J.; Vacca, J. P.; Williams, P. D.; Bohn, D.; Clayton, F. C.; Cook, J. J.; Krueger, J. A.; Kuo, L. C.; Lewis, S. D.; Lucas, B. J.; McMasters, D. R.; Miller-Stein, C.; Pietrak, B. L.; Wallace, A. A.; White, R. B.; Wong, B.; Yan, Y.; Nantermet, P. G. Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors. J. Med. Chem. 2004, 47, 2995-3008.
36. Skrzypczak-Jankun, E.; Carperos, V. E.; Ravichandran, K. G.; Tulinsky, A.; Westbrook, M.; Maraganore, J. M. Structure of the hirugen and hirulog 1 complexes of α-thrombin. J. Mol. Biol. 1991, 221, 1379-1393.
37. Sharff, A. J. High throughput crystallography on an in-house source, using ACTOR. Rigaku J. 2004, 20, 10.
38. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
39. Carr, R. A.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: leads by design. Drug Discovers Today 2005, 10, 987-992.
40. Breinlinger, E. C.; Keenan, C. J.; Rotello, V. M. Modulation of flavin recognition and redox properties through donor atom-π interactions. J. Am. Chem. Soc. 1998. 120, 8606-8609.
41. Rotello, V. M. The donor atom-π interaction of sulfur with flavin. A density functional investigation. Heteroat. Chem. 1998, 9, 605-606.
42. Rossky, P. J.; Karplus, M. Solvation. A molecular dynamics study of a dipeptide in water. J. Am. Chem. Soc. 1979, 101, 1913-1937.
43. Lim, M. S.; Johnston, E. R.; Kettner, C. A. The solution conformation of (D)Phe-Pro-containing peptides: implications on the activity of Ac-(D)Phe-Pro-boroArg-OH, a potent thrombin inhibitor. J. Med. Chem. 1993. 36, 1831-1838.
44. Obst, U.; Banner, D. W.; Weber, L.; Diederich, F. Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin inhibitor complexes. Chem. Biol. 1997, 4, 287-295.
45. Reers, M.; Koschinsky, R.; Dickneite, G.; Hoffmann, D.; Czech, J.; Stuber, W. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. J. Enzyme Inhib. 1995, 9, 61-72.
46. Murray, C. W.; Verdonk, M. L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput.-Aided Mol. Des. 2002, 16, 741-753.
47. Page, M. I.; Jencks, W. P. Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. Proc. Natl. Acad. Sci. U.S.A. 1971, 68, 1678-1683.
48. Ngai, P. K.; Chang, J. Y. A novel one-step purification of human α-thrombin after direct activation of crude prothrombin enriched from plasma. Biochem. J. 1991, 280 (Part 3), 805-808.
49. Pflugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallogr., Sect. D 1999, 55 (Part 10), 1718-1725.
50. Collaborative Computational Project, N. 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr., Sect. D 1994, 50, 760-763.
51. Engh, R. A.; Brandstetter, H.; Sucher, G.; Eichinger, A.; Baumann, U.; Bode, W.; Huber, R.; Poll, T.; Rainer, R.; von der Saal, W. Enzyme flexibility, solvent and "weak" interactions characterize thrombin-ligand interactions: implications for drug design. Structure 1996, 4, 1353-1362.
52. Verdonk, M. L.; Hartshorn, M.; Mooij, W. T. M.; Murray, C. W.; Taylor, R. D.; Watson, P. Virtual screening using protein-ligand docking: avoiding artificial enrichment. J. Chem. Inf. Compui. Sci. 2004, 44(3), 793-806.
53. Maple, J. R.; Hwang, M.-J.; Jalkanen, K. J.; Stockfish, T. P. H. A. T. Derivation of class II force fields: V. Quantum force field for amides, peptides and related compounds. J. Comput. Chem. 1998, 19, 430-458.
54. Barrish, J. C.; Gordon, E.; Alam, M.; Lin, P. F.; Bisacchi, G. S.; Chen, P.; Cheng, P. T.; Fritz, A. W.; Greytok, J. A.; Hermsmeier, M. A. Aminodiol HIV protease inhibitors. I. Design, synthesis, and preliminary SAR. J. Med. Chem. 1994, 37, 1758-1768.
55. Ascenzi, P.; Fruttero, R.; Amiconi, G.; Pugluse, L.; Bolognesi, M.; Massimo, C.; Onesti, S.; Guarneri, M.; Menegatti, E. Inhibition of α-, and β- and γ- thrombin by mono-, bis-, tris- and tetra-benzamidine structures: thermodynamic study. J. Enzyme Inhib. 1992, 6, 131-139, 1992.
56. Magnusson, K. K. A. The binding of proflavin to thrombin. Arch. Biochem. Biophys. 1974, 160, 175-184.